News
SUPN
49.94
-0.34%
-0.17
3 Unprofitable Stocks We Think Twice About
Barchart · 1d ago
Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
TipRanks · 2d ago
Weekly Report: what happened at SUPN last week (0406-0410)?
Weekly Report · 2d ago
Supernus finalizes $350M asset acquisition of Navitor’s SPN-820
Seeking Alpha · 04/08 05:20
Supernus Acquires NV-5138 Asset in New Agreement
TipRanks · 04/07 22:06
Supernus to Acquire Compound From Navitor for Up to $350M
Dow Jones · 04/07 21:59
Supernus Pharmaceuticals Enters Asset Purchase Agreement With Navitor On April 1, 2026; To Buy Assets Related To NV-5138 Or SPN-820, Including IP And Inventory; Purchase Price Includes Phase 2b Study And Milestone Payments Up To $350M; Agreement Includes Five-year Non-Compete And Non-Solicitation Covenant
Benzinga · 04/07 21:31
Supernus enters into asset purchase agreement with Navitor
TipRanks · 04/07 21:30
SUPERNUS PHARMACEUTICALS INC - AGREEMENT INCLUDES FIVE-YEAR NON-COMPETE AND NON-SOLICITATION COVENANT - SEC FILING
Reuters · 04/07 21:26
Supernus buys NV-5138 assets from Navitor in deal with up to $350 million milestones
Reuters · 04/07 21:26
Weekly Report: what happened at SUPN last week (0330-0403)?
Weekly Report · 04/06 09:44
Weekly Report: what happened at SUPN last week (0323-0327)?
Weekly Report · 03/30 09:44
Supernus Pharmaceuticals (SUPN) Gets a Buy from Jefferies
TipRanks · 03/24 13:05
Weekly Report: what happened at SUPN last week (0316-0320)?
Weekly Report · 03/23 09:42
Supernus Sr. VP of IP and CSO Padmanabh P. Bhatt disposes of USD 5.4 million in common shares
Reuters · 03/18 21:19
Weekly Report: what happened at SUPN last week (0309-0313)?
Weekly Report · 03/16 09:42
Top Supernus Director Quietly Unloads a Major Chunk of Stock
TipRanks · 03/10 02:02
Weekly Report: what happened at SUPN last week (0302-0306)?
Weekly Report · 03/09 09:43
Supernus Pharmaceuticals Braces for 2025 U.S. Drug Pricing Orders and MFN Rules That Threaten Revenues and Global Expansion
TipRanks · 03/04 06:01
Supernus Pharmaceuticals Balances Record Sales With Rising Costs
TipRanks · 03/03 00:27
More
Webull provides a variety of real-time SUPN stock news. You can receive the latest news about Supernus Pharma through multiple platforms. This information may help you make smarter investment decisions.
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. It is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.